TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07875881: A Phase 3, Randomized, Double Blind, Placebo Controlled Study of Deutenzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With High-Risk Biochemical Recurrence (BCR) of Prostate Cancer

Sponsor: Hinova Pharmaceuticals Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 1044 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07875881 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07875881 Rescue Dossier →